91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Postmarketing requirements (PMRs) for drug development are commonly required to gather data on a product’s longer-term safety, efficacy and optimal use. Carefully applied AI and machine learning offers the potential for better management of PMRs.
-
This article explores the imperatives and strategies for commercialising oncology treatments targeting young adults, highlighting the need for innovative regulatory and commercial strategies to ensure successful market entry and improved patient outcomes.
-
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
-
91黑料’s Dr Neena Nizar and Dr Jana Benesh discuss the ways effective engagement with PAOs is shaping rare disease research and contributing to better therapeutic outcomes. Read the article in IPI for insights into patient engagement in preclinical, clinical and post-approval phases of development.
-
With more than 170 early stage IPF clinical programs, IPF is one of the most dy?namic rare diseases spaces for development.
-
There is a growing trend among large and midsize pharma in turning toward more strategic partnerships to help them navigate the increasing complexity of the development landscape and the compounding macroeconomic constraints. Read our Whitepaper: Embracing a blended operating model for more details.
-
Innovative laboratory solutions have the potential to optimise clinical research processes, create more efficient operations and improve sustainability to support wider organisational objectives. In this article published by R&D World, 91黑料 outlines some of the new initiatives that are in progress to ensure the continued delivery of high quality results that meet sponsors’ needs – today and tomorrow.
-
This article published in The Pharma Letter highlights findings from an 91黑料 survey has found that despite the increasing investment in emerging oncology-related therapeutics, developers have varied views on the impact of new cancer drugs for patients.
-
Read insights from Harpreet Gill VP, Real World Solutions, on how sponsors can optimise their LTFU studies to be flexible and cost-effective, with strategic planning and innovation, overcoming challenges while capturing valuable data insights.
-
Preventing delays and accelerating the progression of these critical therapies.
